Table 1 Demographic and clinical characteristics of the 41 patients that died due to COVID-19

Female/male

18/23

Caucasians, n (%)

35 (85%)

Age in years, median (range)

55 (22—88)

Body mass index, median (range)

26 (13—48)

Comorbidities, n (%)

Diabetes

13 (32.5%)

Systemic arterial hypertension

20 (50%)

Cardiomyopathy

10 (25%)

Vascular disase

5 (12.5%)

Chronic kidney disease

4 (10%)

Asthma

2 (5%)

Chronic obstructive pulmonary disease

5 (12.5%)

Smoker

4 (10%)

Comorbidities number

 1

20 (54.1%)

 2

10 (27%)

 3

2 (5.4%)

 4

3 (8.1%)

 5

2 (5.4%)

Symptoms, n (%)

Fever

29 (72.5%)

Dyspnoea

33 (82.5%)

Cough

27 (67.5%)

Rhinorrhea

6 (15%)

Diarrhoea

9 (22.5%)

Myalgia

14 (35%)

Sore throat

5 (12.5%)

Nausea and vomiting

10 (25%)

Others

15 (37.5%)

Use of corticosteroids, n (%)

23 (57.5%)

Use of anticoagulants, n (%)

11 (30.8%)

Use of vasoactive drugs (admission), n = 37

15 (40.5%)

Use of mechanical ventilation, n = 37

37 (100%)

Prone positioning, n = 37

12 (32.4%)

Extracorporeal membrane oxygenation, n = 37

4 (10.8%)

Dialysis, n = 37

20 (54.1%)

Glasgow coma scale (day 1), n = 37

3 (3–15)

Simplified acute physiology score III (day 1), n = 37

66 (39–97)

Laboratory parameters from 24 h before death, median (range)

D Dimer (ng/ml), n = 32

4593 (815–126,078)

Fibrinogen (mg/dl), n = 20

485.5 (89–2465)

Platelets (ml/mm³), n = 39

158,000 (4000–322,000)

Activated partial thromboplastin time (s), n = 32

1.23 (0.92–7.0)

Lymphocytes (ml/mm³), n = 39

0.37 (0.04–1.05)

Lung parameters from 24 h before death, median (range)

PEEP (cmH₂O), n = 35

10 (5–20)

FiO₂ (%), n = 35

60 (25–100)

PaO₂/FiO₂ ratio, n = 28

122.5 (56–430)

Time from symptom onset to hospitalization in days, median (range)

5 (0–26)

Time from symptom onset to death in days, median (range)

18 (3–47)

Period of hospitalisation in days, median (range)

12 (0–40)

Intensive care unit stay in days, median (range)

9 (0–38)

Period of mechanical ventilation in days, median (range)

11 (0–39)